ALK-ABELLO A/S [CBOE] news, videos and press releases
For more news please use our advanced search feature.
ALK-ABELLO A/S [CBOE] - More news...
ALK-ABELLO A/S [CBOE] - More news...
- ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review
- Listen in on ALK’s Capital Markets Day on 4 June 2024
- Three-month interim report (Q1) 2024 (unaudited)
- ALK upgrades its full-year revenue outlook
- Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024
- Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
- Save the date for ALK’s Capital Markets Day on 4 June 2024
- Annual General Meeting in ALK-Abelló A/S held on 14 March 2024
- Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
- Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
- Annual General Meeting in ALK-Abelló A/S on 14 March 2024
- Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
- Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
- Annual report 2023: ALK delivers 9% sales growth with profits up 50%
- ALK’s 2030 CO2 reduction targets have been approved by SBTi
- Release date of annual report 2023 for ALK and webcast
- ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review
- ALK completes first part of phase 1 trial with peanut SLIT-tablet
- ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy
- ALK – Financial calendar for the 2024 financial year
- ALK expands partnership with Torii in Japan
- Nine-month interim report (Q3) 2023
- Release date of nine-month interim report (Q3) 2023 for ALK and audio cast
- Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children
- Six-month interim report (Q2) 2023
- Release date of six-month interim report (Q2) 2023 for ALK and audio cast
- President & CEO Carsten Hellmann to step down end 2023. Peter Halling appointed as his successor
- Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s house dust mite tablet in young children
- Three-month interim report (Q1) 2023
- Release date of three-month interim report (Q1) 2023 for ALK and audio cast